Advertisement

Zusammenfassung

Die Hauptindikation für den Einsatz von L-Dopa ist das idiopathische Parkinsonyndrom (IPS). Fast alle Aussagen zu den Therapieerfolgen und den Problemen der Langzeittherapie beziehen sich daher auf dieses Krankheitsbild.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baas H, Fischer PA (1984) Salbengesicht. Zentrale Dysregulation der Talgsekretion beim Parkin-son-Syndrom. In: Fischer PA (Hrsg) Vegetativstörungen beim Parkinson-Syndrom. Edi-tiones Roche, Basel, S 221–233Google Scholar
  2. Balzereit F, Michler M (1982) Psychische Störungen beim Parkinson-Syndrom und ihre Bedeutung für die familiäre und berufliche Situation des Kranken. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 241–251Google Scholar
  3. Barbeau A, Sourkes TL, Murphy GF (1962) Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra (ed) Monoamines et systéme nerveux central. Masson, Paris, pp 247–262Google Scholar
  4. Bateman DN, Kahn C, Legg NJ, Reid JL (1978) Metoclopramide in Parkinson’s disease. Clin Pharmacol Ther 24: 459–464PubMedGoogle Scholar
  5. Bernstein RM (1979) Reversible hemolytic anemia after levodopa-carbidopa. Br Med J I: 1461–1462CrossRefGoogle Scholar
  6. Bianchine JR (1984) Drugs for Parkinson’s disease, centrally acting muscle relaxants. In: Goodman and Gilmans’: The pharmacological basis of therapeutics, 6th ed. Mac Millan, Toronto, Balliere Tindall London, pp 457–493Google Scholar
  7. Birkmayer W, Hornykiewicz O (196l) Der L-Di-oxyphenylalanin (= L-Dopa) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788Google Scholar
  8. Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit. Biochemie, Klinik, Therapie, 2. Aufl. Springer, Wien New YorkGoogle Scholar
  9. Boose PD, Spieker S, Jentgens CH, Klockgether TH, Scholz E, Dichgans J (1994) Assessing tremor severity with long-term tremor recordings. J Neurol Neurosurg Psychiatry 57: 397PubMedCrossRefGoogle Scholar
  10. Braak H, Braak E (1990) Die Beteiligung der entorhinalen Region und der isokortikalen Rinde bei der Parkinson-Krankheit. In: Fischer PA (Hrsg) Parkinson-Krankheit und Nigra-prozess. Editiones Roches, Basel Grenzach-Wyhlen, S 47–53Google Scholar
  11. Braun AR, Tanner CM, Goeth CG, Klawans HL (1983) Respiratory distress due to pharyngeal dystonia: a side effect of chronic dopamine agonism. Neurology 33 [Suppl 2]: 220Google Scholar
  12. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees J, Mathias CJ, Bannister R, Marsden CD, Frackowiak RSJ (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28: 547–555PubMedCrossRefGoogle Scholar
  13. Cantello R, Gilli M, Riccio A, Bergamasco B (1986) Mood changes associated with „end-of-dose deterioration“ in Parkinson’s disease. A controlled study. J Neurol Neurosurg Psychiatry 49: 1182–1190PubMedCrossRefGoogle Scholar
  14. Carter JH, Nutt JG, Woodward WR, Hatcher LF, Trotman BS (1989) Amount and distribution of dietary protein effects clinical response to levodopa in Parkinson’s disease. Neurology 39: 552–556PubMedCrossRefGoogle Scholar
  15. Cedarbaum JM, Kut H, Mc Dowel FH (1989) A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and Standard Sinemet (25/100). Neurology 39 [Suppl 2]: 38–44PubMedGoogle Scholar
  16. Chajek T, Berry EM, Friedman G, Ambransky O (1977) Treatment of acute hepatic encephalopathy with L-Dopa. Postgrad Med J 53: 262–265PubMedCrossRefGoogle Scholar
  17. Clarke CE (1995) Review: Does levodopa therapy delay death in Parkinson’s disease. Mov Disord 10: 250–256PubMedCrossRefGoogle Scholar
  18. Cook DG, Klawans HL (1985) Levodopa during pregnancy. Clin Neuropharmacol 8: 93–95PubMedCrossRefGoogle Scholar
  19. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism — chronic treatment with levodopa. N Engl J Med 280: 337–345PubMedCrossRefGoogle Scholar
  20. Crevoisier C, Hoevels B, Zürcher G, DA Prada M (1987) Bioaviability of L-Dopa after Madopar HBS administration in healthy volunteers. Eur Neurol 27 [Suppl 1]: 36–46PubMedCrossRefGoogle Scholar
  21. Critchley EMR (1976) Peak-dose dysphonia in parkinsonism. Lancet i: 544CrossRefGoogle Scholar
  22. Csoti I, Werner M, Fornadi F (1998) L-Dopa Präparate in gelöster Form — Wirkung auf die frühmorgendliche Akinese. Akt Neurol 25: S 155Google Scholar
  23. Danielczyk W (1978) Akute psychische Störungen während der L-Dopa-Therapie von Parkinson-Kranken. In: Fischer PA (Hrsg) Langzeitbehandlung des Parkinson-Syndroms. Schattauer, Stuttgart, S 211–218Google Scholar
  24. Deuschl G (1992) Tremor. In: Hopf HC, Poeck K, Schliack H (Hrsg) Neurologie in Praxis und Klinik. Thieme, Stuttgart New York, 4.53–4.61Google Scholar
  25. Diamond SG, Markham CH, Treciokas LJ (1976) Long-term experience with L-Dopa: efficacy, progression, and mortality. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roches, Basel, pp 444–455Google Scholar
  26. Diamond SG, Markham CH, Hoehn MM, Mc Dowel FH, Muenter MD (1987) Multicenter study of parkinson mortality with early versus later dopa treatment. Ann Neurol 22: 8–12PubMedCrossRefGoogle Scholar
  27. Direnfeld LK, Feldman RG, Alexander MP, Kelly-Hayes M (1980) Is L-Dopa drug holiday useful? Neurology 30: 785–788PubMedCrossRefGoogle Scholar
  28. Djaldetti R, Achiron A, Ziv I, Dabby R, Mosberg R, Melamed E (1994) The effect of Sinemet tablet versus suspension of crushed Sinemet on „delayed on“ and „no-on“ fluctuations in Parkinson’s disease. Neurology 44: 245AGoogle Scholar
  29. Dupont E, Hansen E, Nelsen S, Pakkenberg H, Holm P (1972) Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor Ro 4-4602 (a comparison with levodopa treatment alone). Acta Neurol Scand [Suppl 51]: 115–117Google Scholar
  30. Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Kjaer MO, Kristensen N, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Bach D (1996) Sustained-release Madopar HBS® compared with standard Madopar® in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93: 14–20PubMedCrossRefGoogle Scholar
  31. Duvoisin RC (ed) (1989) New strategies in the dopaminergic therapy of Parkinson’s disease: the use of a controlled release formulation. Neurology [Suppl 2] 39: 1–106Google Scholar
  32. Duvoisin RC, Lobo-Antunes J, Yahr MD (1972) Response of patients with postencephalitic parkinsonism. Trans Am Neurol Assoc 94: 81–84Google Scholar
  33. Fahn S (1989) Adverse effects of levodopa in Parkinson’s disease. In: Calne CD (ed) Drugs for the treatment of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 385–409CrossRefGoogle Scholar
  34. Fahn S, Barrett RB (1979) Increase in parkinsonian symptoms as a manifestation of levodopa toxicity. Adv Neurol 24: 451–459Google Scholar
  35. Fahn S, Bressman SB (1984) Should levodopa therapy of parkinsonism be started early or rate? Evidence against early treatment. Can J Neurol Sci 11: 200–206PubMedGoogle Scholar
  36. Fermaglich J, Delaney P (1977) Parkinson’s disease, melanoma, and levodopa. J Neurol 215: 221–224PubMedCrossRefGoogle Scholar
  37. Fischer PA, Schneider E, Jacobi P (1982) Depressive Verstimmungen bei Parkinson-Kranken im Langzeitverlauf. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 139–152Google Scholar
  38. Fischer PA, Schneider E, Jacobi P (1983) Klinische Bilder des Parkinson-Syndroms und ihre Verläufe. In: Gänshirt H, Berlit P, Haack G (Hrsg) Pathophysiologic, Klinik und Therapie des Parkinsonismus. Editiones Roches, Basel, S 51–66Google Scholar
  39. Fischer PA, Przuntek H, Rajer H, Wetzel D (1984) Kombinationsbehandlung früher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Dtsch Med Wochenschr 109:1279–1283PubMedCrossRefGoogle Scholar
  40. Fornadi F, Milani F, Werner M (1994) Madopar dispersible in the treatment of advanced Parkinson’s disease. Clin Neuropharmacol 17 [Suppl 3]: 7–15CrossRefGoogle Scholar
  41. Friedman JH, Feinberg SS, Feldman RG (1985) A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA 254: 2792–2795PubMedCrossRefGoogle Scholar
  42. Friedman A, Sienkiewics J (1991) Psychotic complications of long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 84:111–113PubMedCrossRefGoogle Scholar
  43. Gancher ST, Nutt JG, Woodward W (1988) Response to brief levodopa infusions in Parkinsonian patients with and without motor fluctuations. Neurology 38: 712–716PubMedCrossRefGoogle Scholar
  44. Gardener WN, Langdon N, Parkes JD (1986) Breathing in Parkinson’s disease. Adv Neurol 45: 271–274Google Scholar
  45. Gauthier G (1972) Long-term study. Laboratory findings. Hoffmann La Roche, BaselGoogle Scholar
  46. Glantz R, Goetz CG, Nausieda A (1981) Effect of bromocriptine on the on-off phenomena. J Neural Transm 1: 735–738Google Scholar
  47. Golbe LI (1987) Parkinson’s disease and pregnancy. Neurology 37: 1245–1249PubMedCrossRefGoogle Scholar
  48. Golbe LI, Duvoisin RC (1987) Double blind trial of R-deprenyl for the on-off effect complicating Parkinson’s disease. J Neural Transm [Suppl 25]: 123–130Google Scholar
  49. Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neuro-surg Psychiatry 49: 381–389CrossRefGoogle Scholar
  50. Grahnén A, Eckernäs S-Å, Collin C, Ling-Anderson A, Tiger G, Nilsson M (1992) Comparison multidose pharmacokinetics of controlled-re-lease levodopa products. Eur Neurol 32: 343–348PubMedCrossRefGoogle Scholar
  51. Hefner R, Fischer PA(1989) Zunahme der Parkinson-Symptomatik unter Kalzium-Antagoni-sten. Nervenarzt 60: 187–188PubMedGoogle Scholar
  52. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427–442PubMedCrossRefGoogle Scholar
  53. Hoehn MM, Rutledge CO (1975) Acute overdose with levodopa. Clinical and biochemical consequences. Neurology 25: 792–794Google Scholar
  54. Hovestadt A, Bogaard JM, Meerwaldt JD, VAN DER Meché FGA, Stigt J (1989) Pulmonary function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52: 329–333PubMedCrossRefGoogle Scholar
  55. Hutton JT (1996) CR First study: results of a 5-year comparative trial of Sinemet CR vs standard Sinemet in treatment of levodopa-naive patients with Parkinson’s disease. Efficacy analysis. 4th International Congress of Movement Disorders, June 16–21 1996, Vienna, AustriaGoogle Scholar
  56. Jansen E (1978) Bromocriptine in levodopa response loosing parkinsonism. Eur Neurol 17: 92–99PubMedCrossRefGoogle Scholar
  57. Kapp W (1982) Diskussionsbemerkung. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 272–273Google Scholar
  58. Kaye JA, Feldman RG (1986) The role of L-dopa holiday in the long-term management of Parkinson’s disease. Clin Neuropharmacol 9: 1–13PubMedCrossRefGoogle Scholar
  59. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AL, Stern GM (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52: 718–723PubMedCrossRefGoogle Scholar
  60. Kendel K, Beck U, Wita C, Zimmermann H (1972) Der Einfluß von L-Dopa auf den Nachtschlaf bei Patienten mit Parkinson-Syndrom. Arch Psychiat Nervenkr 216: 82–100PubMedCrossRefGoogle Scholar
  61. Klawans HL, Goetz C, Bergen D (1975) Levo-dopa-induced myoclonus. Arch Neurol 32: 331–334CrossRefGoogle Scholar
  62. Kofman OS (1984) Are levodopa „drug holidays“ justified? Can J Neurol Sci 11: 206–209PubMedGoogle Scholar
  63. Koller WC, Poewe W (eds) (1994) Long-acting Levodopa preparations in the management of Parkinson’s disease. Clin Neuropharmacol [Suppl 2] 17: 1–44Google Scholar
  64. Kurland R, Rubin AJ, Miller CH, Rivera-Calimlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for „on-off“ fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262–265CrossRefGoogle Scholar
  65. Kurtzke JF, Murphy FM (1990) The changing patterns of death rates in parkinsonism. Neurology 40: 42–49PubMedCrossRefGoogle Scholar
  66. Langrall HM, Joseph C (1972) Evaluation of safety and efficacy of levodopa in Parkinson’s disease and syndrome. Neurology [Suppl] 22: 3–16CrossRefGoogle Scholar
  67. Leenders KL, Palmers AJ, Quinn NP, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860PubMedCrossRefGoogle Scholar
  68. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260PubMedCrossRefGoogle Scholar
  69. Le Witt PA (1995) Therapies to extend duration of levodopa action. In: Koller WC, Paulson G (eds) Therapy of Parkinson’s disease. Marcel Dekker, New York Basel Hongkong, pp 77–89Google Scholar
  70. Lieberman A (1993) Combination therapy of Parkinson’s disease. Neurology 43: 2725–2726PubMedCrossRefGoogle Scholar
  71. Lieberman AN, Shupack JL (1974) Levodopa and melanoma. Neurology 24: 340–343PubMedCrossRefGoogle Scholar
  72. Limousin P, Pollak P, Pfefen JP, Tournier-Gerva-Son CL, Dubuis R, Perret JE (1995) Acute administration of levodopa-benserazide and Tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin Neuropharmacol 18: 258–265PubMedCrossRefGoogle Scholar
  73. Lücking CH, Deuschl G, Strahl G, Schenk E (1986) Tremor im Früh-und Spätstadium der Parkinson-Krankheit. In: Fischer PA (Hrsg) Spätsyndrome der Parkinson-Krankheit. Edi-tiones Roches, Basel, S 99–114Google Scholar
  74. Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 31: 125–131PubMedCrossRefGoogle Scholar
  75. Markham CH, Diamond SG (1986) Long-term follow-up of early DOPA treatment in Parkinson’s disease. Ann Neurol 19: 362–365CrossRefGoogle Scholar
  76. Marsden CD, Rinne UK, Koella WP, Dubuis R (eds) (1987) Madopar HNBS. Eur Neurol 27 [Suppl]: 1–140Google Scholar
  77. Mayeux R, Stern Y, Mulvey K, Cote L (1985) Reappraisal of temporary levodopa withdrawal („drug holiday“) in Parkinson’s disease. N Engl J Med 313: 724–733PubMedCrossRefGoogle Scholar
  78. Neu HC, Connolly JJ, Schwertley FW, Ladwig HA, Brody AW (1967) Obstructive respiratory dysfunction in parkinsonian patients. Am Rev Resp Dis 95: 33–47PubMedGoogle Scholar
  79. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham A-M, Marsden CD (1987) Mood swinge associated with the „on-off“ phenomenon in Parkinson’s disease. Psychol Med 17: 899–904PubMedCrossRefGoogle Scholar
  80. Nugent CA, Harris HW, Cohn J, Smith CG, Tyler FH (1958) Dyspnea as a symptom in Parkinson’s disease. Am Rev Tuberkulosis 78: 682–691Google Scholar
  81. Nutt JG, Carter JH, Woodward WR (1994a) Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 44: 1617–1622PubMedCrossRefGoogle Scholar
  82. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammer-Stad JP, Gordin A (1994b) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913–919PubMedCrossRefGoogle Scholar
  83. Nygaard TG, Marsden CD, Duvoisin RC (1988) Dopa-responsive dystonia. Adv Neurol 50: 377–384PubMedGoogle Scholar
  84. Nygaard TG, Marsden CD, Fahns S (1991) Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 41: 174–181PubMedCrossRefGoogle Scholar
  85. Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Nikkelsen B, Presthus J, Rautakorpi J, Riman E, Rinne UK (1976) Parkinson’s disease treated with Sinemet or Madopar. Acta Neurol Scand 53: 376–385PubMedCrossRefGoogle Scholar
  86. Paulseth JE, Jensen JJ, Klawans HL (1985) Dom-peridone therapy in patients with Parkinson’s disease with levodopa-carbidopa related gastrointestinal complaints. Ann Neurol 18: 127–131Google Scholar
  87. Pincus JH, Barry K (1987a) Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 44: 270–272PubMedCrossRefGoogle Scholar
  88. Pincus JH, Barry K (1987b) Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 44: 1006–1009PubMedCrossRefGoogle Scholar
  89. Pinter MM, Mamoli BT (1995) L-Dopa plus Decar-boxylasehemmer Standardform/Retardform. Neuropsychiatrie [Suppl] 9: 4–9Google Scholar
  90. Poewe W, Lees AJ, Stern GM (1986) Low dose L-Dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 36: 1528–1530PubMedCrossRefGoogle Scholar
  91. Poewe W, Kleedorfer B, Gerstenbrand F, Oertel WH (1989) Die Behandlung von Parkinson-Patienten mit L-Dopa-Wirkungsfluktuationen mittels subkutaner Apomorphingaben. Akt Neurol 16: 73–77CrossRefGoogle Scholar
  92. Quinn NP, Parkes JD, Marsden CD (1984) Control of „on-off“ phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedCrossRefGoogle Scholar
  93. Quinn NP, Koller WC, Lang AE, Marsden CD (1986) Painful Parkinson’s disease. Lancet i: 1366–1369CrossRefGoogle Scholar
  94. Rabey JM (1991) Late addition of dopamine agonists in Parkinson’s disease. In: Rinne UK, Nagatsu T, Horowski R (eds) International workshop Berlin Parkinson’s disease. Medi-com, Bussum, pp 283–295Google Scholar
  95. Rajfer SL, Anton AH, Rossen JD, Goldberg LL (1984) Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. N Engl J Med 310: 1357–1362PubMedCrossRefGoogle Scholar
  96. Rajput AH, Offord KP, Beard CM, Kurland LT (1984a) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16: 278–282PubMedCrossRefGoogle Scholar
  97. Rajput AH, Stern W, Laverty WH (1984b) Chronic low dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 39: 991–996CrossRefGoogle Scholar
  98. Reyntjens A, Verlinden M, DE Coster R, Janisch HD, Smonte A, DE Cree J, Leempoels J, Verhagen H (1984) Clinical pharmacological evidence for cisapride’s lack of antidopaminergic or direct cholinergic properties. Curr Ther Res 36: 1045–1052Google Scholar
  99. Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–828PubMedCrossRefGoogle Scholar
  100. Rinne UK, Sonninen V, Siirtola T (1970) Treatment of Parkinson’s disease with L-Dopa and decarboxylase inhibitor. Z Neurol 203: 1–20Google Scholar
  101. Sabaté M, Rodriguez M, Méndez E, Enriquez E, Conzalez I (1996) Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson’s disease. Arch Phys Med Rehabil 77: 29–34PubMedCrossRefGoogle Scholar
  102. Sacks O (1983) Awakenings. Dutton, New York, pp 1–338Google Scholar
  103. Sage I, Duvoisin RC (1986) Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy. Mov Disord 1: 267–270PubMedCrossRefGoogle Scholar
  104. Schärer K (1971) Die Alters-und Wachstumsabhängigkeit der durch den Decarboxylase-hemmer Ro 4-4602 verursachten Skelettveränderungen und ihre Bedeutung für den Parkinson-Patienten. Rapport Nr 78.086, Hoffmann La RocheGoogle Scholar
  105. Schneider E, Maxion H, Ziegler B, Jacobi P (1974) Das Schlafverhalten von Parkinson-Kranken und seine Beeinflussung durch L-Dopa. J Neurol 207: 95–108PubMedCrossRefGoogle Scholar
  106. Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinsonsyndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiat 52: 207–214PubMedCrossRefGoogle Scholar
  107. Sechi GP, Tanda F, Mutani R (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology 34: 249–251PubMedCrossRefGoogle Scholar
  108. Segawa M, Hosaka A, Miygawa F, Nomura Y, Imai H (1976) Hereditary progressive dystonia with marked diurnal fluctuations. Adv Neurol 14: 215–233PubMedGoogle Scholar
  109. Sober AJ, Wick MM (1978) Levodopa therapy and malignant melanoma. JAMA 240: 554–555PubMedCrossRefGoogle Scholar
  110. Sober AJ, Wick MM (1979) Levodopa and melanoma. JAMA 241: 883Google Scholar
  111. Stibe CMH, Lees AJ, Kempster PA, Stern G (1989) Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet i: 403–406Google Scholar
  112. Stocchi F, Ruggieri S, Monge A, Nordera G, Bolner P, Viselli F, Bramante L, Quinn NP, DE Pandis F, Manfredi M (1994) Clinical efficacy of single morning doses of different levodopa formulations. Clin Neuropharmacol 17 [Suppl 3]: 16–20CrossRefGoogle Scholar
  113. Streifler M, Kesten M, Loewenthal M, Aldor T, Gilat T (1976) Liver function and gastric acid secretion in parkinsonism. Patients under prolonged treatment with L-Dopa and a peripheral decarboxylase inhibitor. Eur Neurol 14: 68–76PubMedCrossRefGoogle Scholar
  114. Tanner, CM, Goetz CG, Klawans HL (1986) Hypersexuality in Parkinson’s disease. Neurology 36 [Suppl 1]: 183Google Scholar
  115. Weiner WJ, Singer C, Sanchez-Ramos JR, Golden-Berg JN (1993) Levodopa, melanoma, and Parkinson’s disease. Neurology 43: 674–677PubMedCrossRefGoogle Scholar
  116. Whitehouse PJ (1986) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer disease. Adv Neurol 45: 393–397Google Scholar
  117. Wick MM (1980) Levodopa and dopamine analoge as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res 40: 1414–1418PubMedGoogle Scholar
  118. Wolters EC, Tesselaar HJM, International (NL & UK) Sinemet CR Study Group (1996) International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson’s disease. J Neurol 243: 235–240PubMedCrossRefGoogle Scholar
  119. Woofter MJA, Manyam BV (1994) Safety of longterm levodopa therapy in malignant melanoma. Clin Neuropharmacol 18: 315–319CrossRefGoogle Scholar
  120. Yahr MD (1976) Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykie-Wicz O (eds) Advances in parkinsonism. Editiones Roches, Basel, pp 435–443Google Scholar
  121. Yahr MD, Wolf A, Antunes JL, Miyoshi K, Duffy P (1972) Autopsy findings in parkinsonism following treatment with levodopa. Neurology 22 [Suppl]: 56–71CrossRefGoogle Scholar
  122. ZIEGLER M, RANOUX D, DE RECONDO J (1994)Clinical efficacy of a liquid formulation of levodopa (Madopar dispersible) in reversing afternoon „off“ periods in Parkinson’s disease. Clin Neutropharmacol 17 [Suppl 3]: 21–25Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • E. Schneider

There are no affiliations available

Personalised recommendations